Search All Resources
Peer Support Specialists: A New Perspective in Non-traditional Settings | September 28, 2022
Type: Past Presentation
Audience: Clinical Community
Program: Hepatitis C
Keywords: #hcv #peer support #Peers #Recovery #SUD
In this presentation, O’Nesha Cochran, a certified peer recovery mentor, shares her story and provides an overview of peer recovery support, how people interested in peer recovery can become certified, and potential barriers to peer support.
Date added: 09/28/22
Choosing to Start HCV Elimination | August 24, 2022
Type: Past Presentation
Audience: Clinical
Program: Hepatitis C
Keywords: #elimination #hcv #hepatitis #hepc #pharmacist #pharmacy #pharmacy-based clinic #viral
In this presentation, Dr. Whitney Dickson, PharmD, presents on her efforts and lessons learned in starting an HCV Elimination Program at Cass Lake IHS. Dr. Dickson discusses understanding the need for HCV services, summarizes the steps taken to start an ...
Date added: 08/22/22
Hepatitis B and D Coinfection | August 17, 2022
Type: Past Presentation
Program: Hepatitis C
Keywords: #hbv #HDV #hepatitis #hepatitis b #hepatitis d
In this presentation, Dr. Paulina Deming, ECHO faculty member and Associate Professor of Pharmacy at the University of New Mexico Sciences Center, discusses background data on global hepatitis D virus (HDV) prevalence, patients who may be at risk for HDV, ...
Date added: 08/17/22
Buprenorphine: Prescribing and Review of Literature (Part 2) | August 3, 2022
Type: Past Presentation
Audience: Clinical
Program: Hepatitis C
Keywords: #benzo #benzodiazepine #bup #buprenorphine #hcv #induction #naloxone #opioid use disorder #OUD
In this presentation, Dr. Jasen Christensen presents on buprenorphine and other options for managing opioid use disorder. Dr. Christensen reviews buprenorphine induction, literature informing current prescribing best practices, and discusses data supporting buprenorphine for chronic pain.
Date added: 08/3/22
Hepatitis B Virus | July 27 2022
In this presentation Dr. Karla Thornton discusses Hepatitis B Virus and serology interpretation. She describes the modes of transmission for HBV, how to identify appropriate baseline serologies for HBV and how to correctly interpret serologic tests for HBV.
Date added: 07/27/22
Common Drug-Drug Interactions with HCV DAAs | June 22, 2022
Type: Past Presentation
Audience: Clinical
Program: Hepatitis C
Keywords: #drug interactions #hcv #hcv cure #hcv treatment #hep c #hepatitis
In this presentation, Bradley Moran, PharmD, shares a valuable overview of common medication interactions with hepatitis C medications.
Date added: 06/22/22
Indian Country ECHO Treatment Recommendation Analysis | April 27, 2022
Type: Past Presentation
Audience: Clinical
Program: Hepatitis C
Keywords: #hcv #hcv cure #hcv treatment #hep c #hepatitis
In this presentation, Ashley Wirth, MD/MCR candidate, discusses "Results from an Analysis of Indian Country HCV ECHO Case Forms and Treatment Recommendations" from years 2017-2021. In her presentation she highlights; determining how many patients received treatment recommendations for HCV treatment ...
Date added: 04/27/22
MAT and the HCV Provider | March 23, 2022
Type: Past Presentation
Program: Hepatitis C
Keywords: #harm reduction #hcv treatment #mat #OUD #SUD
In this presentation Dr. Jessica Gregg provides an overview of screening, treatment options, and individualized care for patients with substance use disorder and hepatitis C virus. The trifecta of interventions needed include treating the HCV infection with antivirals, decreasing the ...
Date added: 03/23/22
Residual Risk for HCC in Patients After HCV SVR | February 23, 2022
Type: Past Presentation
Audience: Clinical
Program: Hepatitis C
Keywords: #cure #hcc #hepatocellular carcinoma #svr
In this presentation, Dr. Raymond Chung, 2021 AASLD President and Director of Hepatology and the Liver Center at Massachusetts General Hospital, discusses the residual risk for hepatocellular carcinoma in patients after achieving cure from hepatitis C virus.
Date added: 02/22/22
Fentanyl’s Rising Presence in Oregon | October 27, 2021
In this presentation, guests from Overdose Data to Action: Oregon HOPE discuss the rising prevalence of fentanyl in substances used, share insight from interviews with persons who are currently exposed to risks of fentanyl, and highlight how we may better ...
Date added: 10/27/21